Keywords
Biochemical markers
Depressive symptoms
Mediation analysis
National Health and Nutrition Examination Survey
Categories
How to Cite
Abstract
Chronic kidney disease (CKD) is a clinical syndrome characterised by declining renal function, linked to depressive symptoms, though the mediating role of biochemical markers in this association remains unclear. We downloaded and analyzed data from the National Health and Nutrition Examination Survey (NHANES) spanning from 2005 to 2018. This study employed multivariate logistic regression, restricted cubic spline models, subgroup analyses, and interaction tests to investigate the association between CKD and depressive symptoms. Additionally, mediation analyses assessed the potential role of biochemical markers in the relationship between CKD and depressive symptoms. A total of 2902 CKD participants were included, with 291 presenting depressive symptoms, and estimated glomerular filtration rate (eGFR) was negatively associated with depressive symptoms with full adjustment [odds ratio (OR), 0.98; 95% confidence interval (95% CI), 0.97–1.00]. After converting eGFR to a categorical variable by quartiles (Q1-Q4), compared to Q1, the highest eGFR quartile was linked to a significantly decreased likelihood of depressive symptoms (OR=0.53, 95% CI: 0.30–0.92). Subgroup analysis further revealed a negative relationship between eGFR and depressive symptoms. Mediation analysis indicated that six biochemical markers mediated the association between CKD and depressive symptoms, with the following contributions: 49.72% for blood urea nitrogen, 17.82% for alkaline phosphatase, 17.21% for albumin, 9.78% for globulin, 8.94% for iron, and 6.95% for glucose. In this cross-sectional analysis, lower eGFR was associated with higher presence of depressive symptoms. Blood urea nitrogen, alkaline phosphatase, albumin, globulin, iron, and glucose mediated the association of CKD on depressive symptoms.
References
[1] S. Stewart, P.A. Kalra, T. Blakeman, E. Kontopantelis, H. Cranmer-Gordon, and S. Sinha, Chronic kidney disease: detect, diagnose, disclose-a UK primary care perspective of barriers and enablers to effective kidney care. BMC Med 22 (2024) 331.
[2] C.P. Kovesdy, Epidemiology of chronic kidney disease: an update 2022. Kidney Int Suppl (2011) 12 (2022) 7-11.
[3] Global, regional, and national burden of chronic kidney disease, 1990-2017: a systematic analysis for the Global Burden of Disease Study 2017. Lancet 395 (2020) 709-733.
[4] P. Bouwmans, S.R.K. Malahe, A.L. Messchendorp, P. Vart, C. Imhof, J.F. Sanders, R.T. Gansevoort, A.P.J. de Vries, A.C. Abrahams, F.J. Bemelman, J.P.M. Vervoort, L.B. Hilbrands, M. Ten Dam, R.M.A. van den Dorpel, T. Rispens, M. Steenhuis, M.E.J. Reinders, and M.H. Hemmelder, Post COVID-19 condition imposes significant burden in patients with advanced chronic kidney disease: A nested case-control study. Int J Infect Dis 142 (2024) 106990.
[5] A. Artborg, A. Caldinelli, J. Wijkström, A. Nowak, M. Fored, M. Stendahl, M. Evans, and H. Rydell, Risk factors for COVID-19 hospitalization and mortality in patients with chronic kidney disease: a nationwide cohort study. Clin Kidney J 17 (2024) sfad283.
[6] C.D. Mathers, and D. Loncar, Projections of global mortality and burden of disease from 2002 to 2030. PLoS Med 3 (2006) e442.
[7] K.J. Foreman, N. Marquez, A. Dolgert, K. Fukutaki, N. Fullman, M. McGaughey, M.A. Pletcher, A.E. Smith, K. Tang, C.W. Yuan, J.C. Brown, J. Friedman, J. He, K.R. Heuton, M. Holmberg, D.J. Patel, P. Reidy, A. Carter, K. Cercy, A. Chapin, D. Douwes-Schultz, T. Frank, F. Goettsch, P.Y. Liu, V. Nandakumar, M.B. Reitsma, V. Reuter, N. Sadat, R.J.D. Sorensen, V. Srinivasan, R.L. Updike, H. York, A.D. Lopez, R. Lozano, S.S. Lim, A.H. Mokdad, S.E. Vollset, and C.J.L. Murray, Forecasting life expectancy, years of life lost, and all-cause and cause-specific mortality for 250 causes of death: reference and alternative scenarios for 2016-40 for 195 countries and territories. Lancet 392 (2018) 2052-2090.
[8] A. Bautovich, I. Katz, M. Smith, C.K. Loo, and S.B. Harvey, Depression and chronic kidney disease: A review for clinicians. Aust N Z J Psychiatry 48 (2014) 530-41.
[9] S.S. Hedayati, A.T. Minhajuddin, R.D. Toto, D.W. Morris, and A.J. Rush, Prevalence of major depressive episode in CKD. Am J Kidney Dis 54 (2009) 424-32.
[10] R.C. Kessler, P. Berglund, O. Demler, R. Jin, D. Koretz, K.R. Merikangas, A.J. Rush, E.E. Walters, and P.S. Wang, The epidemiology of major depressive disorder: results from the National Comorbidity Survey Replication (NCS-R). Jama 289 (2003) 3095-105.
[11] W. Xu, Z. Chen, Y. Zhang, J. Zhao, W. Huang, X. Guo, and J. Zhang, Mapping the global research landscape on depression for patients with chronic kidney disease: a bibliometric and visualized analysis from 2006 to 2022. Front Pharmacol 15 (2024) 1388641.
[12] E.L. Knight, N. Ofsthun, M. Teng, J.M. Lazarus, and G.C. Curhan, The association between mental health, physical function, and hemodialysis mortality. Kidney Int 63 (2003) 1843-51.
[13] A.A. Lopes, J. Bragg, E. Young, D. Goodkin, D. Mapes, C. Combe, L. Piera, P. Held, B. Gillespie, and F.K. Port, Depression as a predictor of mortality and hospitalization among hemodialysis patients in the United States and Europe. Kidney Int 62 (2002) 199-207.
[14] M. Liu, Y. Zhang, S. Yang, Q. Wu, Z. Ye, C. Zhou, P. He, Y. Zhang, F.F. Hou, and X. Qin, Bidirectional relations between depression symptoms and chronic kidney disease. J Affect Disord 311 (2022) 224-230.
[15] I. Ohno, Relationship between hyperuricemia and chronic kidney disease. Nucleosides Nucleotides Nucleic Acids 30 (2011) 1039-44.
[16] S.J. Barbour, L. Er, O. Djurdjev, M.A. Karim, and A. Levin, The prevalence of hematologic and metabolic abnormalities during chronic kidney disease stages in different ethnic groups. Kidney Int 74 (2008) 108-14.
[17] Y.N. Wang, S.X. Ma, Y.Y. Chen, L. Chen, B.L. Liu, Q.Q. Liu, and Y.Y. Zhao, Chronic kidney disease: Biomarker diagnosis to therapeutic targets. Clin Chim Acta 499 (2019) 54-63.
[18] A. Sheinenzon, M. Shehadeh, R. Michelis, E. Shaoul, and O. Ronen, Serum albumin levels and inflammation. Int J Biol Macromol 184 (2021) 857-862.
[19] T. Yamaguchi, I. Shioji, A. Sugimoto, and M. Yamaoka, Psychological stress increases bilirubin metabolites in human urine. Biochem Biophys Res Commun 293 (2002) 517-20.
[20] M. Rengasamy, and R. Price, Replicable and robust cellular and biochemical blood marker signatures of depression and depressive symptoms. Psychiatry Res 342 (2024) 116190.
[21] H. Levassort, J. Boucquemont, O. Lambert, S. Liabeuf, S.M. Laville, L. Teillet, A.H. Tabcheh, L. Frimat, C. Combe, D. Fouque, M. Laville, C. Jacquelinet, C. Helmer, N. Alencar de Pinho, M. Pépin, Z.A. Massy, and C. On Behalf Of Ckd-Rein Study, Urea Level and Depression in Patients with Chronic Kidney Disease. Toxins (Basel) 16 (2024).
[22] S.H. Song, I.J. Kim, S.J. Kim, I.S. Kwak, and Y.K. Kim, Cerebral glucose metabolism abnormalities in patients with major depressive symptoms in pre-dialytic chronic kidney disease: statistical parametric mapping analysis of F-18-FDG PET, a preliminary study. Psychiatry Clin Neurosci 62 (2008) 554-61.
[23] M. Rengasamy, E.S.S.A. Da Costa, M. Spada, and R.B. Price, Does the moderator matter? Identification of multiple moderators of the association between peripheral inflammatory markers and depression severity in a large racially diverse community cohort. Neuropsychopharmacology 47 (2022) 1693-1701.
[24] Y. Sun, Z. Fu, Q. Bo, Z. Mao, X. Ma, and C. Wang, The reliability and validity of PHQ-9 in patients with major depressive disorder in psychiatric hospital. BMC Psychiatry 20 (2020) 474.
[25] B. Levis, A. Benedetti, and B.D. Thombs, Accuracy of Patient Health Questionnaire-9 (PHQ-9) for screening to detect major depression: individual participant data meta-analysis. Bmj 365 (2019) l1476.
[26] L.T. Park, and C.A. Zarate, Jr., Depression in the Primary Care Setting. N Engl J Med 380 (2019) 559-568.
[27] D.C. Team, DecisionLinnc. 1.0. https://www.statsape.com/. (2023).
[28] Z. Zhang, P. He, M. Liu, C. Zhou, C. Liu, H. Li, Y. Zhang, Q. Li, Z. Ye, Q. Wu, G. Wang, M. Liang, and X. Qin, Association of Depressive Symptoms with Rapid Kidney Function Decline in Adults with Normal Kidney Function. Clin J Am Soc Nephrol 16 (2021) 889-897.
[29] G. Juszczyk, J. Mikulska, K. Kasperek, D. Pietrzak, W. Mrozek, and M. Herbet, Chronic Stress and Oxidative Stress as Common Factors of the Pathogenesis of Depression and Alzheimer's Disease: The Role of Antioxidants in Prevention and Treatment. Antioxidants (Basel) 10 (2021).
[30] M. Adzic, Z. Brkic, M. Mitic, E. Francija, M.J. Jovicic, J. Radulovic, and N.P. Maric, Therapeutic Strategies for Treatment of Inflammation-related Depression. Curr Neuropharmacol 16 (2018) 176-209.
[31] B. Afsar, The relationship of serum cortisol levels with depression, cognitive function and sleep disorders in chronic kidney disease and hemodialysis patients. Psychiatr Q 85 (2014) 479-86.
[32] S. Mihai, E. Codrici, I.D. Popescu, A.M. Enciu, L. Albulescu, L.G. Necula, C. Mambet, G. Anton, and C. Tanase, Inflammation-Related Mechanisms in Chronic Kidney Disease Prediction, Progression, and Outcome. J Immunol Res 2018 (2018) 2180373.
[33] T. Asao, K. Oki, M. Yoneda, J. Tanaka, and N. Kohno, Hypothalamic-pituitary-adrenal axis activity is associated with the prevalence of chronic kidney disease in diabetic patients. Endocr J 63 (2016) 119-26.
[34] S.F. Sorrells, J.R. Caso, C.D. Munhoz, and R.M. Sapolsky, The stressed CNS: when glucocorticoids aggravate inflammation. Neuron 64 (2009) 33-9.
[35] M.R. Irwin, and A.H. Miller, Depressive disorders and immunity: 20 years of progress and discovery. Brain Behav Immun 21 (2007) 374-83.
[36] P.D. Loprinzi, and S. Mahoney, Concurrent occurrence of multiple positive lifestyle behaviors and depression among adults in the United States. J Affect Disord 165 (2014) 126-30.
[37] M. Adjibade, C. Lemogne, C. Julia, S. Hercberg, P. Galan, K.E. Assmann, and E. Kesse-Guyot, Prospective association between combined healthy lifestyles and risk of depressive symptoms in the French NutriNet-Santé cohort. J Affect Disord 238 (2018) 554-562.
[38] C. Garofalo, S. Borrelli, R. Minutolo, P. Chiodini, L. De Nicola, and G. Conte, A systematic review and meta-analysis suggests obesity predicts onset of chronic kidney disease in the general population. Kidney Int 91 (2017) 1224-1235.
[39] J.T. Kelly, G. Su, L. Zhang, X. Qin, S. Marshall, A. González-Ortiz, C.M. Clase, K.L. Campbell, H. Xu, and J.J. Carrero, Modifiable Lifestyle Factors for Primary Prevention of CKD: A Systematic Review and Meta-Analysis. J Am Soc Nephrol 32 (2021) 239-253.
[40] B.J. Lee, Association of depressive disorder with biochemical and anthropometric indices in adult men and women. Sci Rep 11 (2021) 13596.
[41] Y.F. Peng, Y. Xiang, and Y.S. Wei, The significance of routine biochemical markers in patients with major depressive disorder. Sci Rep 6 (2016) 34402.
[42] Y. Mao, X. Li, S. Zhu, J. Ma, Y. Geng, and Y. Zhao, Associations between urea nitrogen and risk of depression among subjects with and without type 2 diabetes: A nationwide population-based study. Front Endocrinol (Lausanne) 13 (2022) 985167.
[43] H. Wang, B. Huang, W. Wang, J. Li, Y. Chen, T. Flynn, M. Zhao, Z. Zhou, X. Lin, Y. Zhang, M. Xu, K. Li, K. Tian, D. Yuan, P. Zhou, L. Hu, D. Zhong, S. Zhu, J. Li, D. Chen, K. Wang, J. Liang, Q. He, J. Sun, J. Shi, L. Yan, J.M. Sands, Z. Xie, X. Lian, D. Xu, J. Ran, and B. Yang, High urea induces depression and LTP impairment through mTOR signalling suppression caused by carbamylation. EBioMedicine 48 (2019) 478-490.
[44] X. Li, J. Ran, H. Zhou, T. Lei, L. Zhou, J. Han, and B. Yang, Mice lacking urea transporter UT-B display depression-like behavior. J Mol Neurosci 46 (2012) 362-72.
[45] A. Sciacqua, G. Tripepi, M. Perticone, V. Cassano, T.V. Fiorentino, G.N. Pititto, R. Maio, S. Miceli, F. Andreozzi, G. Sesti, and F. Perticone, Alkaline phosphatase affects renal function in never-treated hypertensive patients: effect modification by age. Sci Rep 10 (2020) 9847.
[46] KDIGO 2017 Clinical Practice Guideline Update for the Diagnosis, Evaluation, Prevention, and Treatment of Chronic Kidney Disease-Mineral and Bone Disorder (CKD-MBD). Kidney Int Suppl (2011) 7 (2017) 1-59.
[47] W. Zhou, Y. Jin, Q. Meng, X. Zhu, T. Bai, Y. Tian, Y. Mao, L. Wang, W. Xie, H. Zhong, N. Zhang, M.H. Luo, W. Tao, H. Wang, J. Li, J. Li, B.S. Qiu, J.N. Zhou, X. Li, H. Xu, K. Wang, X. Zhang, Y. Liu, G. Richter-Levin, L. Xu, and Z. Zhang, A neural circuit for comorbid depressive symptoms in chronic pain. Nat Neurosci 22 (2019) 1649-1658.
[48] L. Zhang, I.K. Adu, H. Zhang, and J. Wang, The WNT/β-catenin system in chronic kidney disease-mineral bone disorder syndrome. Int Urol Nephrol 55 (2023) 2527-2538.
[49] G. Zhang, S. Li, S. Wang, F. Deng, X. Sun, and J. Pan, The association between serum albumin and depressive symptoms: a cross-sectional study of NHANES data during 2005-2018. BMC Psychiatry 23 (2023) 448.
[50] Y.P. Sheng, X.Y. Ma, Y. Liu, X.M. Yang, and F.Y. Sun, Independent risk factors for depression in older adult patients receiving peritoneal dialysis for chronic kidney disease. World J Psychiatry 13 (2023) 884-892.
[51] H.J. Hsu, C.H. Yen, C.K. Chen, I.W. Wu, C.C. Lee, C.Y. Sun, S.J. Chang, C.C. Chou, M.F. Hsieh, C.Y. Chen, C.Y. Hsu, C.J. Tsai, and M.S. Wu, Association between uremic toxins and depression in patients with chronic kidney disease undergoing maintenance hemodialysis. Gen Hosp Psychiatry 35 (2013) 23-7.
[52] T. Cheng, X. Wang, Y. Han, J. Hao, H. Hu, and L. Hao, The level of serum albumin is associated with renal prognosis and renal function decline in patients with chronic kidney disease. BMC Nephrol 24 (2023) 57.
[53] J. Lang, R. Katz, J.H. Ix, O.M. Gutierrez, C.A. Peralta, C.R. Parikh, S. Satterfield, S. Petrovic, P. Devarajan, M. Bennett, L.F. Fried, S.R. Cummings, M.J. Sarnak, and M.G. Shlipak, Association of serum albumin levels with kidney function decline and incident chronic kidney disease in elders. Nephrol Dial Transplant 33 (2018) 986-992.
[54] J. Park, H.J. Kim, J. Kim, Y.B. Choi, Y.S. Shin, and M.J. Lee, Predictive value of serum albumin-to-globulin ratio for incident chronic kidney disease: A 12-year community-based prospective study. PLoS One 15 (2020) e0238421.
[55] T. Liu, S. Zhong, X. Liao, J. Chen, T. He, S. Lai, and Y. Jia, A Meta-Analysis of Oxidative Stress Markers in Depression. PLoS One 10 (2015) e0138904.
[56] M. Maes, I. Mihaylova, M. Kubera, J.C. Leunis, and M. Geffard, IgM-mediated autoimmune responses directed against multiple neoepitopes in depression: new pathways that underpin the inflammatory and neuroprogressive pathophysiology. J Affect Disord 135 (2011) 414-8.
[57] M. Maes, H.Y. Meltzer, S. Scharpé, E. Bosmans, E. Suy, I. De Meester, J. Calabrese, and P. Cosyns, Relationships between lower plasma L-tryptophan levels and immune-inflammatory variables in depression. Psychiatry Res 49 (1993) 151-65.
[58] J.D. Schaechter, and R.J. Wurtman, Serotonin release varies with brain tryptophan levels. Brain Res 532 (1990) 203-10.
[59] L. Del Vecchio, D. Girelli, F. Vinchi, M. Cozzolino, S. Elliott, P.B. Mark, L. Valenti, C. Qian, Q. Guo, Z.M. Qian, P. Ciceri, and F. Locatelli, Iron biology. Nephrol Dial Transplant 39 (2024) 1404-1415.
[60] C. Berthou, J.P. Iliou, and D. Barba, Iron, neuro-bioavailability and depression. EJHaem 3 (2022) 263-275.
[61] H.S. Lee, H.H. Chao, W.T. Huang, S.C. Chen, and H.Y. Yang, Psychiatric disorders risk in patients with iron deficiency anemia and association with iron supplementation medications: a nationwide database analysis. BMC Psychiatry 20 (2020) 216.
[62] J. Qiu, F. Lian, and X. Fang, Iron status and mental disorders: A Mendelian randomization study. Front Nutr 9 (2022) 1084860.
[63] H. Pei, X. Su, S. Wu, and Z. Wang, Evaluating the impact of chronic kidney disease and the triglyceride-glucose index on cardiovascular disease: mediation analysis in the NHANES. BMC Public Health 24 (2024) 2750.
[64] H. Kamada, F. Yu, C. Nito, and P.H. Chan, Influence of hyperglycemia on oxidative stress and matrix metalloproteinase-9 activation after focal cerebral ischemia/reperfusion in rats: relation to blood-brain barrier dysfunction. Stroke 38 (2007) 1044-9.
[65] W. Rungratanawanich, Y. Qu, X. Wang, M.M. Essa, and B.J. Song, Advanced glycation end products (AGEs) and other adducts in aging-related diseases and alcohol-mediated tissue injury. Exp Mol Med 53 (2021) 168-188.
[66] K. Byun, D. Bayarsaikhan, E. Bayarsaikhan, M. Son, S. Oh, J. Lee, H.I. Son, M.H. Won, S.U. Kim, B.J. Song, and B. Lee, Microglial AGE-albumin is critical in promoting alcohol-induced neurodegeneration in rats and humans. PLoS One 9 (2014) e104699.
[67] D.Y. Lee, Y.H. Cho, M. Kim, C.W. Jeong, J.M. Cha, G.H. Won, J.S. Noh, S.J. Son, and R.W. Park, Association between impaired glucose metabolism and long-term prognosis at the time of diagnosis of depression: Impaired glucose metabolism as a promising biomarker proposed through a machine-learning approach. Eur Psychiatry 66 (2023) e21.
[68] S.M. Gold, O. Köhler-Forsberg, R. Moss-Morris, A. Mehnert, J.J. Miranda, M. Bullinger, A. Steptoe, M.A. Whooley, and C. Otte, Comorbid depression in medical diseases. Nat Rev Dis Primers 6 (2020) 69.
[69] S.W. Chen, X. Li, X. Lang, J. Li, and X.Y. Zhang, Metabolic parameters and thyroid hormones in relation to suicide attempts in patients with first-episode and drug-naive major depressive disorder with comorbid glucose disturbances: a large cross-sectional study. Eur Arch Psychiatry Clin Neurosci 273 (2023) 199-207.
This work is licensed under a Creative Commons Attribution 4.0 International License.
Copyright (c) 2025 Frontiers in Preventive Medicine